Brain-death donors as an alternative source of human stromal mesenchymal cells for cell-based therapy

ConclusionAdequate procedures were developed for BM collection and processing, as well as for in vitro culture, immunophenotyping and differentiation. Fourteen donor-matched BM samples (IC and F) were processed from seven deceased donors (Table 1). Our results show that it is possible to obtain viable hMSC from both sites. Although the total number of mononuclear cells (MNC) per gram of BM appears to be greater in the CI than in F, no statistically significant differences were observed between both sources. Neither the total content of fibroblastoid colony-forming units (CFU-F) per gram of BM nor the amount of CFU-F per MNC differ significantly. The comparative analysis of MSC yields showed that there were no significant differences in MSC obtained per gram of IC-BM or F-BM during the first three passages of cell culture. Furthermore, there were no statistical differences in cell doubling time and population duplications. Cultured cells from both sites exhibited the ability to adhere to plastic and express CD105, CD73, CD90 but not CD45, CD34, CD14 markers by flow cytometry analysis. Trilineage differentiation was also achieve, meeting the ISCT minimum criteria to define hMSC. These results show the feasibility to obtain hMSC from two sites in BDD, and underscores the potential of this new source as a suitable allogeneic source of hMSC for cell-based therapies.
Source: Cytotherapy - Category: Cytology Source Type: research